Literature DB >> 21431452

Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats.

Helena Colom1, Irene Alfaras, Mònica Maijó, M Emília Juan, Joana M Planas.   

Abstract

PURPOSE: To develop a population pharmacokinetic (PK) model which allowed the simultaneous modeling of trans-resveratrol and its glucuronide and sulfate conjugates.
METHODS: Male Sprague-Dawley rats were administered i.v. and p.o. with 2, 10 and 20 mg·kg(-1) of trans-resveratrol. Blood was collected at different times during 24 h. An integrated PK model was developed using a sequential analysis, with non-linear mixed effect modeling (NONMEM). A prediction-corrected visual predictive check (pcVPC) was used to assess model performance. The model predictive capability was also evaluated with simulations after the i.v. administration of 15 mg·kg(-1) that were compared with an external data set.
RESULTS: Disposition PK of trans-resveratrol and its metabolites was best described by a three-linked two-compartment model. Clearance of trans-resveratrol by conversion to its conjugates occurred by a first-order process, whereas both metabolites were eliminated by parallel first-order and Michaelis-Menten kinetics. The pcVPC confirmed the model stability and precision. The final model was successfully applied to the external data set showing its robustness.
CONCLUSIONS: A robust population PK model has been built for trans-resveratrol and its glucuronide and sulfate conjugates that adequately predict plasmatic concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431452     DOI: 10.1007/s11095-011-0395-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

2.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

3.  Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink.

Authors:  A Hem; A J Smith; P Solberg
Journal:  Lab Anim       Date:  1998-10       Impact factor: 2.471

4.  Resveratrol is absorbed in the small intestine as resveratrol glucuronide.

Authors:  G Kuhnle; J P Spencer; G Chowrimootoo; H Schroeter; E S Debnam; S K Srai; C Rice-Evans; U Hahn
Journal:  Biochem Biophys Res Commun       Date:  2000-05-27       Impact factor: 3.575

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 6.  Resveratrol bioavailability and toxicity in humans.

Authors:  Charles-Henry Cottart; Valérie Nivet-Antoine; Christelle Laguillier-Morizot; Jean-Louis Beaudeux
Journal:  Mol Nutr Food Res       Date:  2010-01       Impact factor: 5.914

7.  Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes.

Authors:  Allan Lançon; Nathalie Hanet; Brigitte Jannin; Dominique Delmas; Jean-Marie Heydel; Gérard Lizard; Marie-Christine Chagnon; Yves Artur; Norbert Latruffe
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

8.  Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC.

Authors:  M Emília Juan; Monica Maijó; Joana M Planas
Journal:  J Pharm Biomed Anal       Date:  2009-04-05       Impact factor: 3.935

9.  Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.

Authors:  Alexandra Maier-Salamon; Birigt Hagenauer; Gottfried Reznicek; Thomas Szekeres; Theresia Thalhammer; Walter Jäger
Journal:  J Pharm Sci       Date:  2008-04       Impact factor: 3.534

10.  Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells.

Authors:  Nicole Sabolovic; Anne-Claude Humbert; Anna Radominska-Pandya; Jacques Magdalou
Journal:  Biopharm Drug Dispos       Date:  2006-05       Impact factor: 1.627

View more
  16 in total

1.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

2.  In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.

Authors:  Satish Sharan; Otito F Iwuchukwu; Daniel J Canney; Cheryl L Zimmerman; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

3.  Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury.

Authors:  Joseph H Holthoff; Zhen Wang; Kathryn A Seely; Neriman Gokden; Philip R Mayeux
Journal:  Kidney Int       Date:  2011-10-05       Impact factor: 10.612

Review 4.  Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.

Authors:  Ana Cláudia Santos; Irina Pereira; Mariana Magalhães; Miguel Pereira-Silva; Mariana Caldas; Laura Ferreira; Ana Figueiras; António J Ribeiro; Francisco Veiga
Journal:  AAPS J       Date:  2019-04-23       Impact factor: 4.009

5.  Pulmonary metabolism of resveratrol: in vitro and in vivo evidence.

Authors:  Satish Sharan; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2013-03-08       Impact factor: 3.922

6.  Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.

Authors:  Sascha Venturelli; Alexander Berger; Alexander Böcker; Christian Busch; Timo Weiland; Seema Noor; Christian Leischner; Sabine Schleicher; Mascha Mayer; Thomas S Weiss; Stephan C Bischoff; Ulrich M Lauer; Michael Bitzer
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

7.  Resveratrol, a natural antioxidant, has a protective effect on liver injury induced by inorganic arsenic exposure.

Authors:  Zhigang Zhang; Li Gao; Yanyan Cheng; Jing Jiang; Yan Chen; Huijie Jiang; Hongxiang Yu; Anshan Shan; Baojing Cheng
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

8.  Resveratrol and Montelukast Alleviate Paraquat-Induced Hepatic Injury in Mice: Modulation of Oxidative Stress, Inflammation, and Apoptosis.

Authors:  Noha A El-Boghdady; Nourtan F Abdeltawab; Mohammed M Nooh
Journal:  Oxid Med Cell Longev       Date:  2017-10-22       Impact factor: 6.543

9.  Physical and Pharmacokinetic Characterizations of trans-Resveratrol (t-Rev) Encapsulated with Self-Assembling Lecithin-based Mixed Polymeric Micelles (saLMPMs).

Authors:  Tzu-Pin Li; Wan-Ping Wong; Ling-Chun Chen; Chia-Yu Su; Lih-Geeng Chen; Der-Zen Liu; Hsiu-O Ho; Ming-Thau Sheu
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 10.  Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability.

Authors:  Nikola Gligorijević; Dragana Stanić-Vučinić; Mirjana Radomirović; Marija Stojadinović; Urmila Khulal; Olgica Nedić; Tanja Ćirković Veličković
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.